Gastrointestinal toxicities of novel agents in cancer therapy
A Asnacios, S Naveau, G Perlemuter - European Journal of Cancer, 2009 - Elsevier
A Asnacios, S Naveau, G Perlemuter
European Journal of Cancer, 2009•ElsevierCancer is the second cause of death in Western countries and its incidence continues to
increase. There has also been increase in the elderly population of patients with a good
performance status for whom a proposition of specific cancer treatment should be made. For
the last 10 years, there has been a revolution with regards to the development of novel
agents refered to as “targeted therapy”. Indeed, the better understanding of mechanisms of
oncogenesis has led to the development of new anti-cancer molecules, and many agents …
increase. There has also been increase in the elderly population of patients with a good
performance status for whom a proposition of specific cancer treatment should be made. For
the last 10 years, there has been a revolution with regards to the development of novel
agents refered to as “targeted therapy”. Indeed, the better understanding of mechanisms of
oncogenesis has led to the development of new anti-cancer molecules, and many agents …
Cancer is the second cause of death in Western countries and its incidence continues to increase. There has also been increase in the elderly population of patients with a good performance status for whom a proposition of specific cancer treatment should be made.
For the last 10 years, there has been a revolution with regards to the development of novel agents refered to as “targeted therapy”. Indeed, the better understanding of mechanisms of oncogenesis has led to the development of new anti-cancer molecules, and many agents have been developed recently with different sites of action.
Elsevier
